Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.13.12.7: firefly luciferase

This is an abbreviated version!
For detailed information about firefly luciferase, go to the full flat file.

Word Map on EC 1.13.12.7

Reaction

D-firefly luciferin
+
O2
 +
ATP
=
firefly oxyluciferin
 +
CO2
 +
AMP
 +
diphosphate
 +
hnu

Synonyms

AL1, AL2, beetle luciferase, CBG99luc, CBRluc, FFL, firefly luciferase, firefly luciferin luciferase, fluc, LpLuc1, LpLuc2, Luc, Luc1, Luc1-type luciferase, Luc2, Luc2-type luciferase, luciferase, luciferase (firefly luciferin), luciferase FM, luciferin, Luciola italica luciferase, lucPpe, lucPpy, orange light-producing luciferase, oxygen 4-oxidoreductase, PC3-Luc, Photinus luciferin 4-monooxygenase (ATP-hydrolyzing), Photinus pyralis luciferase, PML, PpLase, Ppy, Ppy GR-TS, Ppy RE-TS, PpyWT, PsntWT

ECTree

     1 Oxidoreductases
         1.13 Acting on single donors with incorporation of molecular oxygen (oxygenases)
             1.13.12 With incorporation of one atom of oxygen (internal monooxygenases or internal mixed-function oxidases)
                1.13.12.7 firefly luciferase

Inhibitors

Inhibitors on EC 1.13.12.7 - firefly luciferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2E)-1-(1-benzofuran-2-yl)-3-(4-methylphenyl)prop-2-en-1-one
-
-
(2E)-1-(1-benzofuran-2-yl)-3-phenylprop-2-en-1-one
-
-
(2E)-1-(2-hydroxyphenyl)-3-(4-methylphenyl)prop-2-en-1-one
-
-
(2E)-1-(5-chlorothiophen-2-yl)-3-(4-methylphenyl)prop-2-en-1-one
-
-
(2E)-1-(5-chlorothiophen-2-yl)-3-phenylprop-2-en-1-one
-
-
(2E)-2-benzylidene-3,4-dihydronaphthalen-1(2H)-one
-
(2E)-2-[(2-bromophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(2-chlorophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(2-methoxyphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(2-methylphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(2-nitrophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(3-bromophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(3-chlorophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(3-methoxyphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(3-methylphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(3-nitrophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-bromophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-chlorophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-ethoxyphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-ethylphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-fluorophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-hydroxyphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-methoxyphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-methylphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(4-nitrophenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[(pyridin-3-yl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[[4-(benzyloxy)phenyl]methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[[4-(diethylamino)phenyl]methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[[4-(dimethylamino)phenyl]methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[[4-(dimethylamino)phenyl]methylidene]-6-methoxy-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[[4-(dimethylamino)phenyl]methylidene]-7-methoxy-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[[4-(dimethylamino)phenyl]methylidene]-8-methoxy-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[[4-(methylsulfanyl)phenyl]methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-2-[[4-(trifluoromethyl)phenyl]methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-5-methoxy-2-[(4-methylphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-6-methoxy-2-[(4-methylphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-7-methoxy-2-[(4-methylphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2E)-8-methoxy-2-[(4-methylphenyl)methylidene]-3,4-dihydronaphthalen-1(2H)-one
-
-
(2R)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanoic acid
common name indoprofen
(2Z)-1-(4-chlorophenyl)-3-(pyridin-2-ylamino)prop-2-en-1-one
-
(2Z)-3-[(2-bromophenyl)amino]-1-pyridin-2-ylprop-2-en-1-one
-
(2Z)-3-[(4-fluorophenyl)amino]-1-furan-2-ylprop-2-en-1-one
-
(2Z)-3-[[4-(dimethylamino)cyclohexa-1,5-dien-1-yl]amino]-1-phenylprop-2-en-1-one
-
(3Z)-3-[[4-(dimethylamino)phenyl]methylidene]-1,3-dihydro-2H-indol-2-one
common name SU4312
(6E)-6-[(3-carboxy-4-hydroxyphenyl)methylidene]-5-oxo-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
-
-
(7E)-7-[(4-methylphenyl)methylidene]-8-oxo-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
-
-
1-phenyl-3-(5-phenylpyridin-2-yl)urea
-
10 microM, 20% inhibition
1-[3-(6-ethoxy-1,3-benzothiazol-2-yl)thiophen-2-yl]urea
-
2,4-dimethoxy-N-(5-methylpyridin-2-yl)benzamide
2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one
common name PD98059
2-(2-chlorophenyl)-6-methoxy-1,3-benzothiazole
-
2-(2-fluorophenyl)-6-methoxy-1,3-benzothiazole
2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-yl)-1-(4-methylphenyl)ethanone
common name pifithrin-alpha
2-(2-methoxyphenyl)-1,3-benzothiazole
2-(3,4-dimethoxyphenyl)-1,3-benzothiazole
2-(3,4-dimethoxyphenyl)-6-methoxy-1,3-benzothiazole
2-(3-fluorophenyl)-1,3-benzothiazole
2-(3-fluorophenyl)-6-methoxy-1,3-benzothiazole
2-(4-chlorophenyl)-1,3-benzothiazole
2-(4-chlorophenyl)-6-methoxy-1,3-benzothiazole
2-(4-ethoxyphenyl)-4-[(4-methylpiperazin-1-yl)carbonyl]quinoline
-
2-(4-ethoxyphenyl)-4-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]quinoline
-
2-(4-fluorophenyl)-6-methoxy-1,3-benzothiazole
2-(4-methoxyphenyl)-1,3-benzothiazole
2-(4-methylphenyl)-4-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]quinoline
-
2-(5-biphenyl-4-yl-1,2,4-oxadiazol-3-yl)pyridine
2-(5-furan-2-yl-1,2,4-oxadiazol-3-yl)pyridine
2-(5-naphthalen-2-yl-1,2,4-oxadiazol-3-yl)pyridine
-
2-(5-pyridin-4-yl-1,2,4-oxadiazol-3-yl)pyridine
2-(6'-hydroxy-2'-benzothiazolyl)-4-hydroxymethylthiazole
-
competitive inhibitor
2-([7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
2-benzylidene-1H-indene-1,3(2H)-dione
-
-
2-hydroxy-5-[(E)-(1-oxo-3,4-dihydronaphthalen-2(1H)-ylidene)methyl]benzoic acid
-
-
2-hydroxy-N'-[(1E)-(2-hydroxyphenyl)methylidene]benzohydrazide
common name SCS
2-methyl-6-(phenylethynyl)pyridine
common name MPEB
2-methyl-6-[(Z)-2-phenylethenyl]pyridine
common name SIB1893
2-phenylbenzothiazole
-
2-[(4-methylphenyl)methylidene]-1H-indene-1,3(2H)-dione
-
-
2-[(4-methylphenyl)methyl]-3,4-dihydronaphthalen-1(2H)-one
-
-
2-[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]pyridine
2-[5-(3,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl]pyridine
-
2-[5-(3-chloro-4-methylphenyl)-1,2,4-oxadiazol-3-yl]pyridine
-
2-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]pyridine
-
2-[5-(5-bromofuran-2-yl)-1,2,4-oxadiazol-3-yl]pyridine
-
2-[[4-(dimethylamino)phenyl]methyl]-3,4-dihydronaphthalen-1(2H)-one
-
-
3',5'-cyclic AMP
3,4-dichloro-N-(5-phenylpyridin-2-yl)benzamide
-
10 microM, 13% inhibition
3,4-dimethoxy-N-(5-phenylpyridin-2-yl)benzamide
-
10 microM, 26% inhibition
-
3,5-diphenyl-1,2,4-oxadiazole
-
-
3-(2-hydroxyphenyl)-1H-benzo[f]chromen-1-one
common name flavonoid
3-(2-methoxyphenyl)-5-phenyl-1,2,4-oxadiazole
3-(4-methylphenyl)-4,5-dihydro-2H-benzo[g]indazole
-
-
3-([7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
3-chloro-N-(5-phenylpyridin-2-yl)benzamide
-
-
3-methyl-2-[(E)-phenyldiazenyl]phenol
3-pyridin-2-yl-1,2,4-oxadiazol-5-yl biphenyl-4-carboxylate
3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
3-[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
3-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
3-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
3-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
3-[5-[2-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
3-[5-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
4-((7-[4-(trifluoromethyl)benzyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)aniline
-
7% inhibition
4-(1,3-benzothiazol-2-yl)-N,N-dimethylaniline
4-(1,3-benzothiazol-2-yl)benzonitrile
4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)-2-(4-ethoxyphenyl)quinoline
-
4-(1-methylethoxy)-N-(5-phenylpyridin-2-yl)benzamide
-
10 microM, 12% inhibition
-
4-(4-aminophenoxy)-7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine
-
-
4-(4-methylphenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine
-
-
4-(5-furan-2-yl-1,2,4-oxadiazol-3-yl)pyridine
4-(6-methoxy-1,3-benzothiazol-2-yl)-N,N-dimethylaniline
4-(6-methoxy-1,3-benzothiazol-2-yl)benzonitrile
4-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)aniline
-
19% inhibition
4-(dimethylamino)-N-(5-phenylpyridin-2-yl)benzamide
-
10 microM, 35% inhibition
4-([2-(methylsulfanyl)-7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
31% inhibition
4-([2-(methylsulfonyl)-7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
9% inhibition
4-([7-(2,2-dimethylpropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)-N,N-dimethylaniline
-
-
4-([7-(2,2-dimethylpropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)-N-methylaniline
-
-
4-([7-(2,2-dimethylpropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
4-([7-(2-methylprop-2-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
4-([7-(2-methylpropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
4-([7-(3-methylbut-2-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
4-([7-(3-methylbutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
4-([7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
26% inhibition
4-([7-(prop-2-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
4-([7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
4-amino-6-[(E)-[4'-[(Z)-(8-amino-1-hydroxy-5,7-disulfonato-6,7-dihydronaphthalen-2-yl)diazenyl]-3-methylbiphenyl-4-yl]diazenyl]-5-hydroxy-2,3-dihydronaphthalene-1,3-disulfonate
common name Evans Blue
4-amino-N-(5-phenylpyridin-2-yl)benzamide
-
-
4-chloro-N-(5-phenylpyridin-2-yl)benzamide
-
-
4-methoxy-N-(5-phenylpyridin-2-yl)benzamide
-
10 microM, 28% inhibition
4-methoxy-N-[(4-methylpyridin-2-yl)carbamoyl]benzamide
-
4-methyl-N-(5-phenylpyridin-2-yl)benzamide
-
10 microM, 18% inhibition
4-methyl-N-(phenylmethyl)benzenesulfonamide
-
-
4-[(7-benzyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]aniline
-
46% inhibition
4-[(7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]aniline
-
-
4-[(7-ethenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]aniline
-
-
4-[(7-ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]aniline
-
-
4-[(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]aniline
-
48% inhibition
4-[1-(1,3-benzothiazol-2-yl)-2-(4-methylpiperazin-1-yl)-2-oxoethyl]phenol
-
4-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]pyridine
4-[5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
4-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
4-[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]-N,N-dimethylaniline
4-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
4-[5-(3-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
-
-
5'-O-[(N-dehydroluciferyl)-sulfamoyl]-adenosine
-
stable and potent reversibel inhibitor
5'-O-[N-(dehydroluciferyl)sulfamoyl]adenosine
competitive inhibitor
5'-O-[[2-(6-hydroxy-1,3-benzothiazol-2-yl)-1,3-thiazole-4-carbonyl]sulfamoyl]adenosine
non-competitive inhibitor
-
5-(2,4-dimethoxyphenyl)-3-phenyl-1,2,4-oxadiazole
5-(2-bromophenyl)-3-(4-methylphenyl)-1,2,4-oxadiazole
-
5-(2-chloro-4-methylphenyl)-3-phenyl-1,2,4-oxadiazole
-
5-(2-fluorophenyl)-3-(4-methoxyphenyl)-1,2,4-oxadiazole
5-(4-fluorophenyl)-3-(3-methylphenyl)-1,2,4-oxadiazole
5-(ethanesulfonyl)-2-(naphthalen-2-yl)-1,3-benzoxazole
non-competitive inhibitor
-
5-anilino-1-naphthalene sulfonate
5-methyl-N-[6-(methylsulfonyl)-1,3-benzothiazol-2-yl]thiophene-2-carboxamide
-
5-naphthalen-2-yl-3-phenyl-1,2,4-oxadiazole
-
5-[(2E)-4-(4-bromophenyl)-4-oxobut-2-en-1-yl]-2-hydroxybenzoic acid
luciferin competitor
-
5-[(E)-(6-bromo-1-oxo-3,4-dihydronaphthalen-2(1H)-ylidene)methyl]-2-hydroxybenzoic acid
-
-
6-methoxy-2-(2-methoxyphenyl)-1,3-benzothiazole
6-methoxy-2-(3-methylphenyl)-1,3-benzothiazole
6-methoxy-2-(4-methoxyphenyl)-1,3-benzothiazole
6-methoxy-2-[2-(2-methylbenzyl)phenyl]-1,3-benzothiazole
-
6-methoxy-2-[3-(2-methylbenzyl)phenyl]-1,3-benzothiazole
-
6-methyl-2-[(Z)-phenyldiazenyl]pyridin-3-ol
common name SIB1757
6-toluidino-2-naphthalene sulfonate
arachidonic acid
concentration above 10 microM
arsenate
bovine serum albumin
-
inhibition when present in large excess
-
butanoic acid
-
IC50: 13.6 mM
CoA
-
above 0.1 mM, N-terminal domain
D-luciferin
-
inhibits CoA-ligase activity with L-luciferin, IC50: 0.135 mM against 0.1 mM L-luciferin
Decanoic acid
-
IC50: 0.0132 mM
dehydroluciferin
dehydroluciferyl adenylate
dehydroluciferyl-adenylate
-
tight-binding competitive inhibitor
dehydroluciferyl-CoA
-
IC50: 0.005 mM
diphosphate
dithiothreitol
-
-
dodecanoic acid
Dodecanol
-
mixed-type inhibitor
dodecylamine
-
noncompetitive inhibitor
ethanol
-
-
ethyl 4-[[2-(4-ethoxyphenyl)quinolin-4-yl]carbonyl]piperazine-1-carboxylate
-
ethyl [4-(4-aminophenoxy)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]acetate
-
33% inhibition
ethyl-2-benzothiazole sulfonate
-
competitive inhibitor
geneticin
-
induces nonsense suppression
gentamicin
-
induces nonsense suppression
Halothane
non-competitive inhibitor
hexadecanoic acid
-
IC50: 0.00067 mM
hexanoic acid
-
IC50: 3.4 mM
iodoacetamide
-
-
L-1-tosylamido-2-phenethyl chlorometyl ketone
-
competitive inhibitor with respect to luciferin, noncompetitive with respect to ATP
L-AMP
a potent luciferase inhibitor
L-luciferin
Limulus amebocyte lysate
-
decreased luminescence intensity to 10%
-
linoleic acid
concentration above 10 microM
Luciferin
MgATP2-
-
-
myristic acid
-
N'-(3-chlorophenyl)-N-[(1Z)-(3-chlorophenyl)methylidene]imidoformamide
common name DCB
N,N-dimethyl-4-([7-(2-methylprop-2-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
N,N-dimethyl-4-([7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
N-(4-ethoxyphenyl)-2-methoxybenzamide
-
N-(5-methylpyridin-2-yl)benzamide
-
-
N-(5-phenylpyridin-2-yl)benzamide
-
10 microM, 27% inhibition
N-(5-phenylpyridin-2-yl)butanamide
-
10 mciroM, 22% inhibition
N-(5-phenylpyridin-2-yl)cyclohexanecarboxamide
-
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-methylfuran-3-carboxamide
-
N-(6-methoxy-1,3-benzothiazol-2-yl)-2-methylfuran-3-carboxamide
-
N-(6-methoxy-1,3-benzothiazol-2-yl)-3-methylthiophene-2-carboxamide
-
-
N-(6-methyl-1,3-benzothiazol-2-yl)thiophene-2-carboxamide
N-(6-phenylpyridin-2-yl)benzamide
-
10 microM, 30% inhibition
N-benzyl-5-phenylpyridin-2-amine
-
10 microM, 20% inhibition
N-ethylmaleimide
-
-
N-methyl-4-([7-(2-methylprop-2-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
N-methyl-4-([7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy)aniline
-
-
N-pyridin-2-ylbenzamide
-
N-quinolin-2-ylbenzamide
-
-
N-tosyl-L-lysine chloromethyl ketone
-
-
N-tosyl-L-phenylalanine chloromethyl ketone
N-[3-(6-methoxy-1,3-benzothiazol-2-yl)phenyl]acetamide
N-[4-(1,3-benzothiazol-2-yl)phenyl]acetamide
N-[5-(3,4-dichlorophenyl)pyridin-2-yl]benzamide
-
10 microM, 4% inhibition
N-[5-(3-chlorophenyl)pyridin-2-yl]benzamide
-
10 microM, 38% inhibition
N-[5-(4-chlorophenyl)pyridin-2-yl]benzamide
-
-
N-[5-(4-methoxyphenyl)pyridin-2-yl]benzamide
-
-
N-[5-(4-methylphenyl)pyridin-2-yl]benzamide
-
10 microM, 51% inhibition
N-[5-(4-tert-butylphenyl)pyridin-2-yl]benzamide
-
10 microM, 49% inhibition
N-[5-[(2,2-dimethylpropanoyl)amino]pyridin-2-yl]-3-hydroxybenzamide
-
N-[5-[4-(1-methylethoxy)phenyl]pyridin-2-yl]benzamide
-
10 microM, 38% inhibition
N-[5-[4-(dimethylamino)phenyl]pyridin-2-yl]benzamide
-
10 microM, 14% inhibition
N-[5-[4-(trifluoromethyl)phenyl]pyridin-2-yl]benzamide
-
10 microM, 39% inhibition
N-[6-(methylsulfonyl)-1,3-benzothiazol-2-yl]thiophene-2-carboxamide
-
NFkappaBAI4
non-competitive inhibitor
-
octadecanoic acid
-
IC50: 0.00063 mM
octanoic acid
-
IC50: 2.9 mM
oleic acid
concentration above 10 microM
oxyluciferin
p-mercuribenzoate
-
-
phenyl (5-phenylpyridin-2-yl)carbamate
-
-
-
phosphate
-
-
pifithrin-alpha
20 microM, above 95% inhibition
Procion blue MX-R
resveratrol
ribose-5-phosphate
-
-
SMT C1100
non-competitive inhibitor, utrophin modulator, phase II clinical compound SMT C1100 for the treatment of Duchenne muscular dystrophy
-
tetradecanoic acid
-
IC50: 0.00068 mM
[2-(4-ethoxyphenyl)quinolin-4-yl][4-(pyridin-2-yl)piperazin-1-yl]methanone
ATP competitor
-
[4-(6-methoxynaphthalen-2-yl)phenyl]acetic acid
luciferin competitor
-
additional information
-